

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus (review of TA397) [ID1591]

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company/sponsor</u></p> <ul style="list-style-type: none"> • GlaxoSmithKline <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action for Sick Children • Action on Pain • Anticoagulation UK • Arthritis Action • Arthritis & Musculoskeletal Alliance • Black Health Agency • British Sjögren's Syndrome Association • Changing Faces • Contact • Disability Rights UK • Genetic Alliance UK • Jnetics • Kidney Care UK • Leonard Cheshire Disability • Let's Face It • Lupus Trust • Lupus UK • National Children's Bureau • National Kidney Federation • National Rheumatoid Arthritis Society • Pain Concern • Pain Relief Foundation • Pain UK • Psoriasis and Psoriatic Arthritis Alliance • Psoriasis Association • Psoriasis Help Organisation • South Asian Health Foundation • Specialised Healthcare Alliance • Thrombosis UK • Versus Arthritis 	<p><u>General commentators</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Cell and Gene Therapy Catapult • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Hospital Information Services - Jehovah's Witnesses • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • NHS England Specialised Rheumatology Clinical Reference Group • Scottish Medicines Consortium • Welsh Health Specialised Services Committee • Welsh Kidney Patients Association <p><u>Comparators</u></p> <ul style="list-style-type: none"> • Baxter Healthcare (cyclophosphamide) • Celltrion (rituximab biosimilar) • Pfizer (cyclophosphamide) • Roche Pharmaceuticals (rituximab) • Sandoz GmbH (rituximab biosimilar) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Bone Research Society

<p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Genetic Nurses & Counsellors • Association of Renal Industries • Association of Renal Technologists • British Association for Surgery of the Knee • British Association of Dermatologists • British Dermatological Nursing Group • British Geriatrics Society • British Institute of Musculoskeletal Medicine • British Myology Society • British Isles Lupus Assessment Group • British Orthopaedic Association • British Orthopaedic Foot and Ankle Society • British Pain Society • British Renal Society • British Skin Foundation • British Society for Allergy and Clinical Immunology • British Society for Children's Orthopaedic Surgery • British Society for Gene and Cell Therapy • British Society for Genetic Medicine • British Society for Haematology • British Society for Haemostasis and Thrombosis • British Society for Human Genetics • British Society for Rheumatology • British Society for Paediatric and Adolescent Rheumatology • British Society of Rehabilitation Medicine • British Thoracic Society • • Clinical Leaders of Thrombosis • Physiotherapy Pain Association • Primary Care Dermatology Society • Primary Care Rheumatology & Musculoskeletal Society • Renal Association • Rheumatoid Arthritis Surgical Society • Royal College of General Practitioners • Royal College of Nursing 	<ul style="list-style-type: none"> • British Epidermo-Epidemiology Society • British Society for Immunology • Centre of Evidence-Based Dermatology, University of Nottingham • Chronic Pain Policy Coalition • Cochrane Cystic Fibrosis & Genetic Disorders Group • Cochrane Musculoskeletal Group • Cochrane Skin Group • Cochrane Vascular • Genomics England • Kidney Research UK • MRC Clinical Trials Unit • National Institute for Health Research • Orthopaedic Research UK • Skin Treatment and Research Trust • Thrombosis Research Institute <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Guidelines Centre <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales
--	---

<ul style="list-style-type: none"> • Royal College of Paediatrics & Child Health • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Endocrinology • Society for Vascular Technology of Great Britain and Ireland • Society of Vascular Nurses • The Vascular Society of Great Britain and Ireland • UK Clinical Pharmacy Association • UK Genetic Testing Network • United Kingdom Primary Immunodeficiency Network • UK Renal Pharmacy Group <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS Bexley CCG • NHS England • NHS West London CCG • Welsh Government 	
--	--

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

MTA Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non- company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, and the British National Formulary).

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee.